PTPN11 inhibitor

DRUG CLASS:

PTPN11 inhibitor

News alerts, weekly reports and conference planners

Related drugs:

KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B	sotorasib + BMS-986466 Sensitive: B - Late Trials sotorasib + BMS-986466 Sensitive : B
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	BMS-986466 Sensitive: C2 – Inclusion Criteria BMS-986466 Sensitive : C2	BMS-986466 Sensitive: C2 – Inclusion Criteria BMS-986466 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RMC-4630 Sensitive: C2 – Inclusion Criteria RMC-4630 Sensitive : C2	RMC-4630 Sensitive: C2 – Inclusion Criteria RMC-4630 Sensitive : C2
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2	ASN007 + ERAS-601 Sensitive: C2 – Inclusion Criteria ASN007 + ERAS-601 Sensitive : C2
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	JAB-21822 + JAB-3312 Sensitive: C2 – Inclusion Criteria JAB-21822 + JAB-3312 Sensitive : C2	JAB-21822 + JAB-3312 Sensitive: C2 – Inclusion Criteria JAB-21822 + JAB-3312 Sensitive : C2
KRAS G12D	Colorectal Cancer	KRAS G12D	Colorectal Cancer	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3	cobimetinib + RMC-4630 Sensitive: C3 – Early Trials cobimetinib + RMC-4630 Sensitive : C3
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3	sotorasib + RMC-4630 Sensitive: C3 – Early Trials sotorasib + RMC-4630 Sensitive : C3
NF1 mutation	Sarcoma	NF1 mutation	Sarcoma	RMC-4630 Sensitive: C4 – Case Studies RMC-4630 Sensitive : C4	RMC-4630 Sensitive: C4 – Case Studies RMC-4630 Sensitive : C4
BRAF mutation	Solid Tumor	BRAF mutation	Solid Tumor	ERAS-601 Sensitive: C4 – Case Studies ERAS-601 Sensitive : C4	ERAS-601 Sensitive: C4 – Case Studies ERAS-601 Sensitive : C4
EML4-ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	EML4-ALK fusion + ALK G1202R	Non Small Cell Lung Cancer	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4
BRAF V600E	Colorectal Cancer	BRAF V600E	Colorectal Cancer	cetuximab + encorafenib + PF-07284892 Sensitive: C4 – Case Studies cetuximab + encorafenib + PF-07284892 Sensitive : C4	cetuximab + encorafenib + PF-07284892 Sensitive: C4 – Case Studies cetuximab + encorafenib + PF-07284892 Sensitive : C4
GOPC-ROS1 fusion + CTNNB1 S45F	Pancreatic Adenocarcinoma	GOPC-ROS1 fusion + CTNNB1 S45F	Pancreatic Adenocarcinoma	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4	lorlatinib + PF-07284892 Sensitive: C4 – Case Studies lorlatinib + PF-07284892 Sensitive : C4
KRAS G12D	Ovarian Serous Adenocarcinoma	KRAS G12D	Ovarian Serous Adenocarcinoma	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4	binimetinib + PF-07284892 Sensitive: C4 – Case Studies binimetinib + PF-07284892 Sensitive : C4
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	osimertinib + BMS-986466 Sensitive: D – Preclinical osimertinib + BMS-986466 Sensitive : D	osimertinib + BMS-986466 Sensitive: D – Preclinical osimertinib + BMS-986466 Sensitive : D
KRAS G12C	Lung Cancer	KRAS G12C	Lung Cancer	sotorasib + RMC-4550 Sensitive: D – Preclinical sotorasib + RMC-4550 Sensitive : D	sotorasib + RMC-4550 Sensitive: D – Preclinical sotorasib + RMC-4550 Sensitive : D
KRAS mutation	Solid Tumor	KRAS mutation	Solid Tumor	SHP099 Sensitive: D – Preclinical SHP099 Sensitive : D	SHP099 Sensitive: D – Preclinical SHP099 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D	SHP099 + SX-682 Sensitive: D – Preclinical SHP099 + SX-682 Sensitive : D
KRAS G12C	Non Small Cell Lung Cancer	KRAS G12C	Non Small Cell Lung Cancer	RG6330 + RLY-1971 Sensitive: D – Preclinical RG6330 + RLY-1971 Sensitive : D	RG6330 + RLY-1971 Sensitive: D – Preclinical RG6330 + RLY-1971 Sensitive : D
NF1 mutation	Non Small Cell Lung Cancer	NF1 mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
BRAF mutation	Non Small Cell Lung Cancer	BRAF mutation	Non Small Cell Lung Cancer	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D	ERAS-601 Sensitive: D – Preclinical ERAS-601 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	gilteritinib + ERAS-601 Sensitive: D – Preclinical gilteritinib + ERAS-601 Sensitive : D	gilteritinib + ERAS-601 Sensitive: D – Preclinical gilteritinib + ERAS-601 Sensitive : D
EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	EGFR C797S + EGFR T790M + EGFR L858R	Non Small Cell Lung Cancer	HBI-2376 Sensitive: D – Preclinical HBI-2376 Sensitive : D	HBI-2376 Sensitive: D – Preclinical HBI-2376 Sensitive : D
KRAS mutation	Pancreatic Ductal Adenocarcinoma	KRAS mutation	Pancreatic Ductal Adenocarcinoma	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D
KRAS mutation	Colorectal Cancer	KRAS mutation	Colorectal Cancer	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D	ASN007 + ERAS-601 Sensitive: D – Preclinical ASN007 + ERAS-601 Sensitive : D
KRAS G12C	Solid Tumor	KRAS G12C	Solid Tumor	TNO155 + JDQ443 Sensitive: D – Preclinical TNO155 + JDQ443 Sensitive : D	TNO155 + JDQ443 Sensitive: D – Preclinical TNO155 + JDQ443 Sensitive : D
KRAS mutation	Non Small Cell Lung Cancer	KRAS mutation	Non Small Cell Lung Cancer	hexachlorophene Sensitive: D – Preclinical hexachlorophene Sensitive : D	hexachlorophene Sensitive: D – Preclinical hexachlorophene Sensitive : D
HER-2 overexpression + KRAS G12C	Non Small Cell Lung Cancer	HER-2 overexpression + KRAS G12C	Non Small Cell Lung Cancer	sotorasib + TNO155 Sensitive: D – Preclinical sotorasib + TNO155 Sensitive : D	sotorasib + TNO155 Sensitive: D – Preclinical sotorasib + TNO155 Sensitive : D

PTPN11 inhibitor

PTPN11 inhibitor

Associations(42)

Associations
(42)